Thera-SAbDab

BIMAGRUMAB

>   Structural Summary
TherapeuticBimagrumab
TargetACVR2B
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTSSYINWVRQAPGQGLEWMGTINPVSGSTSYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGWFDYWGQGTLVTVSS
Light ChainQSALTQPASVSGSPGQSITISCTGTSSDVGSYNYVNWYQQHPGKAPKLMIYGVSKRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCGTFAGGSYYGVFGGGTKLTVL
100% seqID Fv Structure5nhr [Fvs: AB, HL]
99% seqID Fv Structure5ngv [Fvs: HL], 5nh3 [Fvs: HL, IM], 5nhw [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Bimagrumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
bimagrumab Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S
5nh3 E V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
bimagrumab Q S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
5nh3 Q S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
bimagrumab Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S
5nhw E V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
bimagrumab Q S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
5nhw Q S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
Sequence identity: 99.12%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 101 102 103 104 105 106 107 108 109 110 111 112 113
bimagrumab Q V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S
5ngv E V Q L V Q S G A E V K K P G A S V K V S C K A S G Y T F T S S Y I N W V R Q A P G Q G L E W M G T I N P V S G S T S Y A Q K F Q G R V T M T R D T S I S T A Y M E L S R L R S D D T A V Y Y C A R G G W F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
bimagrumab Q S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
5ngv E S A L T Q P A S V S G S P G Q S I T I S C T G T S S D V G S Y N Y V N W Y Q Q H P G K A P K L M I Y G V S K R P S G V S N R F S G S K S G N T A S L T I S G L Q A E D E A D Y Y C G T F A G G S Y Y G V F G G G T K L T V L
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedMorphoSys, Novartis
Conditions Approvedna
Conditions ActiveCachexia, Muscular atrophy, Type 2 diabetes mellitus
Conditions DiscontinuedInclusion body myositis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]